Orchid Pharma Schedules Q3FY26 Earnings Call for Feb 12
Orchid Pharma Limited will host an Analysts/Investors Earnings Call on February 12, 2026, at 4:30 PM IST to discuss Q3FY26 results ended December 31, 2025. Management including MD Manish Dhanuka will attend.
This is a standard disclosure for an upcoming investor call. It does not provide any new material information about the company's performance or strategic direction, hence the impact is considered low.
The announcement is a routine intimation about a scheduled investor call and does not contain any specific financial performance data or forward-looking statements that would indicate a positive or negative sentiment.
Orchid Pharma Limited has announced the schedule for its Analysts/Investors Earnings Call to discuss the financial performance for the Quarter-III of Financial Year 2025-26, which ended on December 31, 2025.
The call is scheduled to be held on Thursday, February 12, 2026, at 04:30 P.M. (IST). The company's management, including Managing Director Mr. Manish Dhanuka, Whole Time Director Mr. Mridul Dhanuka, and Chief Financial Officer Mr. Sunil Kumar Gupta, will be present to address queries.
Systematix Institutional Equities is hosting the call. Details for joining the call, including dial-in numbers and a Diamond Pass registration link, have been provided. The information will also be available on the company's website, www.orchidpharma.com. The company noted that the schedule may be subject to change due to unforeseen circumstances.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.